retatrutide legal status Safety, Side Effects & Provider Use Retatrutide, an experimental weight-loss drug,

Semaglutide carries a boxed warning regarding thyroid C-cell tumors, based on findings in rodent studies showing an increased incidence of medullary thyroid carcinoma

Labs first

Reddam A, McLarnan S, Kupsco A

This weekly dosing schedule is consistent with other agents in the incretin-based injectable class, such as semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro), and is designed to maintain stable plasma drug concentrations throughout the week whilst minimising the burden of frequent injections

If GLP-1 coverage for weight loss is offered, pairing it with lifestyle support through vendors aligned with best practices can improve outcomes